Primary Care Focus Is Key To Bayer's Leading Position In China
This article was originally published in PharmAsia News
Executive Summary
Bayer Schering Pharma didn't become the number one healthcare company in China simply through the merger of Bayer and compatriot Schering AG in 2006. "The pure act of merging would not have been enough; we would only have been number six" in China, explains Liam Condon, managing Director of Bayer HealthCare China, which reported 2008 sales of over $750 million and over 50 percent growth
You may also be interested in...
China's OTC Market: Cardiovascular Are Highly Concerned And Cold And Cough Remains The Most Common Health Issue
SHANGHAI - China's over-the-counter drug market has grown 10 to 15 percent since 2007 and to more than RMB 90 billion ($13 billion) in 2009, according to healthcare market intelligence provider IMS Health
China's OTC Market: Cardiovascular Are Highly Concerned And Cold And Cough Remains The Most Common Health Issue
SHANGHAI - China's over-the-counter drug market has grown 10 to 15 percent since 2007 and to more than RMB 90 billion ($13 billion) in 2009, according to healthcare market intelligence provider IMS Health
China's Health Reform Will Nurture New Drugs, While Boosting Use Of Old Ones - PharmAsia Summit
SAN FRANCISCO - In addition to dramatically increasing access to mainly generic drugs, China's sweeping and upcoming health reform will also include measures designed to spur R&D, according to Song Ruilin, Executive Director-General at the Chinese Pharmaceutical Association's Research Center for Medicinal Policy